Atazanavir (Reyataz).
Atazanavir (Reyataz) is a protease inhibitor that received FDA approval in June 2003. Other approved drugs in this class include amprenavir, indinavir, Kaletra (ritonavir + lopinavir), nelfinavir, ritonavir and saquinavir.
D000069446:Atazanavir Sulfate; D017277:Drug Approval; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate